Europe's first dual orexin receptor antagonist – QUVIVIQ

QUVIVIQ™▼ is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable...

Related Keywords

Allschwil ,Switzerland General ,Switzerland ,Canada ,Norway ,Iceland ,United States ,Paris ,France General ,France ,United Kingdom ,Liechtenstein ,Northern Ireland ,Craigavon ,French ,Great Britain ,American ,Swiss ,Andrewc Weiss ,Jean Paul Clozel ,J Clin Pharmacol ,American Psychiatric Association ,Idorsia Pharmaceuticals Us Inc ,European Council ,Head Of Investor Relations Corporate Communications ,Medicine Society ,Ahead Of The University Hospital ,European Union ,European Union Member States ,Committee For Medicinal Products Human Use ,French Sleep Research ,French Ministry Of Labor ,Idorsia Ltd ,European Commission Decision Reliance Procedure ,Drug Administration ,World Health Organization ,European Commission ,European Department Of Mobility ,Swiss Exchange ,Regulatory Agency ,University Of Pittsburg ,European Board Of The Insomnia Network ,Vigilance Center ,European Medicines Agency ,Idorsia Pharmaceuticals Ltd ,Health Canada ,French National Health Agency ,Paul Clozel ,Chief Executive Officer ,Lancet Neurology ,Product Characteristics ,Paris Cit ,Medicinal Products ,Human Use ,European Economic Area ,European Commission Decision Reliance ,Insomnia Daytime Symptoms ,Impacts Questionnaire ,European Department ,French Ministry ,French Institute ,European Board ,European Insomnia ,Statistical Manual ,Mental Disorders ,Idorsia Pharmaceuticals ,Discov Today Dis ,Clin Sleep ,Vice President ,Investor Relations ,Pharmaceuticals Ltd ,Swiss Stock Exchange Idia ,